[PDF] Top 20 Enunciación de la violencia de género y marco educativo para su prevención
Has 10000 "Enunciación de la violencia de género y marco educativo para su prevención" found on our website. Below are the top 20 most common "Enunciación de la violencia de género y marco educativo para su prevención".
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
... Between February 2002 and June 2003, patients with CIS from 18 European countries, Israel, and Canada were randomized in 98 centers. The inclusion criteria were: age between 18 and 45 years, a first clinical neurological ... See full document
62
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
... the early treatment group gained ...the early treatment group (estimated conversion rate ...(ie, interferon beta-1b drug costs, costs for inpatient and outpatient care, ... See full document
25
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... the treatment of RRMS; to date, there are no head- to-head trials comparing PEG-IFN β -1a to other approved ...no treatment guidelines for practitioners that include initiating or switching to PEG-IFN β ... See full document
9
The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil
... injectable treatment revenues would fall in the coming years in the USA [49], which will probably also happen in Brazil where fingolimod for second-line treatment (after IFN-b or glatiramer failures) and ... See full document
7
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
... the treatment is started with basic therapeutics and the patient is mon- itored clinically with subsequent magnetic resonance imaging ...tolerated treatment, the therapy is ...include interferon-β ... See full document
176
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... IFN beta BaroFeron™, demonstrating acceptable levels of safety and tolerability compared to the marketed ...PEG-IFN beta-1b NU400 derived from aggregate-free IFN NU100 (identical to BaroFeron™) and ... See full document
66
Early stage and long term treatment of multiple sclerosis with interferon-β
... The currently prevalent theory involves the activation of autoreactive type 1 T helper (Th1) cells in the peripheral immune system. Th1 cells are exposed either to self antigens or to molecules that closely mimic them, ... See full document
34
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
... A literature review in the PubMed database was car- ried out, and to our knowledge, this is the sixth case of TMA induced by IFN β . A summary of TMA case reports induced by IFN β is presented in Table 2. In one ... See full document
13
Serial whole brain magnetization transfer imaging in patients with relapsing remitting multiple sclerosis at baseline and during treatment with interferon beta 1b
... The results of our whole-brain histographic analysis confirm the previous findings of van Buchem et al (17, 18) that the MTR histographic peak and mean are decreased in patients with relapsing-remitting MS ... See full document
44
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... with relapsing-remitting MS (RRMS) receiving established 30 mcg weekly intramuscular IFNβ-1a (Avonex, Biogen ...chart review using the following inclusion criteria: RRMS [25], age 18 to 60 years, and an ... See full document
11
SWiss Atorvastatin and Interferon Beta 1b Trial In Multiple Sclerosis (SWABIMS) rationale, design and methodology
... Two experienced observers blinded to both clinical events and treatment are responsible for lesion identification and counting of all scans. Doubtful cases are assessed by consensual agreement. The observers are ... See full document
17
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart<sup>®</sup> in patients with multiple sclerosis
... of age at diagnosis and early treatment, younger patients were those who were most likely to present a relapse dur- ing treatment. Regarding adherence, the data support the conclusion that adherent ... See full document
9
Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort<sup>®</sup> devices
... with relapsing-remitting MS conducted between April 23, 2013 and May 27, 2013 in France, Germany, Italy, and the USA, by an independent market research organization (MRO; Adelphi Research, Bollington, UK), in ... See full document
185
Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials
... number of recurrences in the year preceding the study, which was one of the important covariates. The hazard ratio (relapse rate ratio) of the active group to the placebo group was set at 1/1.3, such the true value of ... See full document
24
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta 1b therapy
... CD80 is a critical costimulatory molecule for development of inflammatory brain disease. It is required for induction of active EAE (8), and EAE-susceptible SJL mice express more CD80 than EAE-resistant B6 mice (16). ... See full document
5
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
... three treatment arms (1:1:1) as follows: PEG-IFN beta-1a at a dose of 125 μ g every 2 weeks (PEG-IFN 2w), PEG- IFN beta-1a at a dose of 125 μ g every 4 weeks (PEG-IFN 4w) and ...years, ... See full document
470
The role of glatiramer acetate in the early treatment of multiple sclerosis
... in multiple aspects, perhaps most importantly by reducing trafficking of activated lymphocytes across the blood–brain barrier (BBB) into the ...produced interferon-beta within the ... See full document
6
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most ... See full document
10
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
... for treatment of relapsing-remitting or active secondary progressive MS, thus enlarging the spectrum of immunological therapies for this debilitating ...β 1b has a significant segment of the drug ... See full document
6
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
... in Multiple Sclerosis (ECTRIMS) meet- ing in ...with relapsing MS already on a stable dose of IFN- β ...β 1b (250 μ g subcutaneously every other ...the interferon-based treatment ... See full document
18
Related subjects